262 related articles for article (PubMed ID: 29859177)
1. Targeting phosphatases of regenerating liver (PRLs) in cancer.
Wei M; Korotkov KV; Blackburn JS
Pharmacol Ther; 2018 Oct; 190():128-138. PubMed ID: 29859177
[TBL] [Abstract][Full Text] [Related]
2. Targeting PRL phosphatases in hematological malignancies.
Xiao S; Chen H; Bai Y; Zhang ZY; Liu Y
Expert Opin Ther Targets; 2024 Apr; 28(4):259-271. PubMed ID: 38653737
[TBL] [Abstract][Full Text] [Related]
3. The double lives of phosphatases of regenerating liver: A structural view of their catalytic and noncatalytic activities.
Gehring K; Kozlov G; Yang M; Fakih R
J Biol Chem; 2022 Jan; 298(1):101471. PubMed ID: 34890645
[TBL] [Abstract][Full Text] [Related]
4. PRL PTPs: mediators and markers of cancer progression.
Bessette DC; Qiu D; Pallen CJ
Cancer Metastasis Rev; 2008 Jun; 27(2):231-52. PubMed ID: 18224294
[TBL] [Abstract][Full Text] [Related]
5. PRL phosphatases as potential molecular targets in cancer.
Stephens BJ; Han H; Gokhale V; Von Hoff DD
Mol Cancer Ther; 2005 Nov; 4(11):1653-61. PubMed ID: 16275986
[TBL] [Abstract][Full Text] [Related]
6. PRL-3 phosphatase and cancer metastasis.
Al-Aidaroos AQ; Zeng Q
J Cell Biochem; 2010 Dec; 111(5):1087-98. PubMed ID: 21053359
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Evaluation of PRL Trimer Disruptors for Novel Anticancer Agents.
Bai Y; Yu ZH; Zhang ZY
Methods Mol Biol; 2016; 1447():121-38. PubMed ID: 27514804
[TBL] [Abstract][Full Text] [Related]
8. Burst kinetics and CNNM binding are evolutionarily conserved properties of phosphatases of regenerating liver.
Fakih R; Goldstein RH; Kozlov G; Gehring K
J Biol Chem; 2023 Apr; 299(4):103055. PubMed ID: 36822330
[TBL] [Abstract][Full Text] [Related]
9. Phosphatase of regenerating liver: a novel target for cancer therapy.
Campbell AM; Zhang ZY
Expert Opin Ther Targets; 2014 May; 18(5):555-69. PubMed ID: 24579927
[TBL] [Abstract][Full Text] [Related]
10. Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis.
Wang Y; Li ZF; He J; Li YL; Zhu GB; Zhang LH; Li YL
Int J Colorectal Dis; 2007 Oct; 22(10):1179-84. PubMed ID: 17440740
[TBL] [Abstract][Full Text] [Related]
11. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Daouti S; Li WH; Qian H; Huang KS; Holmgren J; Levin W; Reik L; McGady DL; Gillespie P; Perrotta A; Bian H; Reidhaar-Olson JF; Bliss SA; Olivier AR; Sergi JA; Fry D; Danho W; Ritland S; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2008 Feb; 68(4):1162-9. PubMed ID: 18281492
[TBL] [Abstract][Full Text] [Related]
12. Physiological and oncogenic roles of the PRL phosphatases.
Hardy S; Kostantin E; Hatzihristidis T; Zolotarov Y; Uetani N; Tremblay ML
FEBS J; 2018 Nov; 285(21):3886-3908. PubMed ID: 29770564
[TBL] [Abstract][Full Text] [Related]
13. Effect of Pharmacological Inhibition of the Catalytic Activity of Phosphatases of Regenerating Liver in Early T Cell Receptor Signaling Dynamics and IL-2 Production.
Aguilar-Sopeña O; Hernández-Pérez S; Alegre-Gómez S; Castro-Sánchez P; Iglesias-Ceacero A; Lazo JS; Roda-Navarro P
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260565
[TBL] [Abstract][Full Text] [Related]
14. Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.
Kobayashi M; Chen S; Gao R; Bai Y; Zhang ZY; Liu Y
Cell Cycle; 2014; 13(18):2827-35. PubMed ID: 25486470
[TBL] [Abstract][Full Text] [Related]
15. Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver.
Hoeger B; Diether M; Ballester PJ; Köhn M
Eur J Med Chem; 2014 Dec; 88():89-100. PubMed ID: 25159123
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Guo K; Tang JP; Tan CP; Wang H; Zeng Q
Cancer Biol Ther; 2008 May; 7(5):750-7. PubMed ID: 18364570
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into molecular function of the metastasis-associated phosphatase PRL-3.
Kozlov G; Cheng J; Ziomek E; Banville D; Gehring K; Ekiel I
J Biol Chem; 2004 Mar; 279(12):11882-9. PubMed ID: 14704153
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
Hwang JJ; Min SH; Sin KH; Heo YS; Kim KD; Yoo OJ; Lee SH
Oncol Rep; 2012 Feb; 27(2):535-40. PubMed ID: 21993571
[TBL] [Abstract][Full Text] [Related]
19. Structural Basis of the Oncogenic Interaction of Phosphatase PRL-1 with the Magnesium Transporter CNNM2.
Giménez-Mascarell P; Oyenarte I; Hardy S; Breiderhoff T; Stuiver M; Kostantin E; Diercks T; Pey AL; Ereño-Orbea J; Martínez-Chantar ML; Khalaf-Nazzal R; Claverie-Martin F; Müller D; Tremblay ML; Martínez-Cruz LA
J Biol Chem; 2017 Jan; 292(3):786-801. PubMed ID: 27899452
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.
Frankson R; Yu ZH; Bai Y; Li Q; Zhang RY; Zhang ZY
Cancer Res; 2017 Nov; 77(21):5701-5705. PubMed ID: 28855209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
